Bis-aromatic anticancer agents

Abstract

Treatment of cancer includes administering a compound of formula (I) to a subject. In particular, treatment of colorectal cancer is described.

1 - 24 . (canceled) 
     
     
         25 . A method of treating cancer in a subject, the method comprising administering to the subject an effective amount of a compound according to formula (II): 
       
         
           
           
               
               
           
         
       
       wherein:
 X is selected from: S; S═O; and SO 2 ; 
 each Z is independently selected from H; C 1-10  alkyl; OR 1 ; halo; ═O; NR 1 R 2 ; NO 2 ; CN; SR 1 ; SO 2 ; COOR 1 ; C 5-12  cycloalkyl; C 5-12  heterocycloalkyl; C 5-12  aryl; and C 5-12  heteroaryl; wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl may be substituted or unsubstituted; 
 each W is independently selected from: C 1-10  alkyl; OR 1 ; halo; NR 1 R 2 ; NO 2 ; CN; SR 1 ; SO 2 ; COOR 1 ; C 5-12  cycloalkyl; C 5-12  heterocycloalkyl; C 5-12  aryl; and C 5-12  heteroaryl; wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl may be substituted or unsubstituted; 
 each R 1  and R 2  is independently H or C 1-10  substituted or unsubstituted alkyl; 
 m is independently an integer from 0 to 10; 
 n is independently an integer from 0 to 10; and 
 each p is independently an integer from 0 to 5; or 
 a pharmaceutically acceptable salt form thereof. 
 
     
     
         26 . The method of  claim 25 , wherein the compound according to formula (II) is selected from: 
       
         
           
           
               
               
           
         
       
       a pharmaceutically acceptable salt form thereof. 
     
     
         27 . The method of  claim 25 , wherein the compound according to formula (II) is: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt form thereof. 
     
     
         28 . The method of  claim 25 , wherein the subject is a human. 
     
     
         29 . The method of  claim 25 , wherein the cancer is selected from: bladder cancer, brain cancer, breast cancer, colorectal cancer, cervical cancer, gastrointestinal cancer, genitourinary cancer, head and neck cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, skin cancer, and testicular cancer. 
     
     
         30 . The method of  claim 29 , wherein the cancer is colorectal cancer. 
     
     
         31 . The method of  claim 29 , wherein the cancer is pancreatic cancer. 
     
     
         32 . The method of  claim 29 , wherein the cancer is prostate cancer. 
     
     
         33 . A method of promoting cell death in a cell, the method comprising contacting the cell with a therapeutically effective amount of a compound of formula (II): 
       
         
           
           
               
               
           
         
       
       wherein:
 X is selected from: S; S═O; and SO 2 ; 
 each Z is independently selected from H; C 1-10  alkyl; OR 1 ; halo; ═O; NR 1 R 2 ; NO 2 ; CN; SR 1 ; SO 2 ; COOR 1 ; C 5-12  cycloalkyl; C 5-12  heterocycloalkyl; C 5-12  aryl; and C 5-12  heteroaryl; wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl may be substituted or unsubstituted; 
 each W is independently selected from: C 1-10  alkyl; OR 1 ; halo; NR 1 R 2 ; NO 2 ; CN; SR 1 ; SO 2 ; COOR 1 ; C 5-12  cycloalkyl; C 5-12  heterocycloalkyl; C 5-12  aryl; and C 5-12  heteroaryl; wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl may be substituted or unsubstituted; 
 each R 1  and R 2  is independently H or C 1-10  substituted or unsubstituted alkyl; 
 m is independently an integer from 0 to 10; 
 n is independently an integer from 0 to 10; and 
 each p is independently an integer from 0 to 5; or 
 a pharmaceutically acceptable salt form thereof. 
 
     
     
         34 . A pharmaceutical composition comprising one or more of a pharmaceutically acceptable carrier, excipient, diluent, or adjuvant; and a compound according to formula (II): 
       
         
           
           
               
               
           
         
       
       wherein:
 X is selected from: S; S═O; and SO 2 ; 
 each Z is independently selected from H; C 1-10  alkyl; OR 1 ; halo; ═O; NR 1 R 2 ; NO 2 ; CN; SR 1 ; SO 2 ; COOR 1 ; C 5-12  cycloalkyl; C 5-12  heterocycloalkyl; C 5-12  aryl; and C 5-12  heteroaryl; wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl may be substituted or unsubstituted; 
 each W is independently selected from: C 1-10  alkyl; OR 1 ; halo; NR 1 R 2 ; NO 2 ; CN; SR 1 ; SO 2 ; COOR 1 ; C 5-12  cycloalkyl; C 5-12  heterocycloalkyl; C 5-12  aryl; and C 5-12  heteroaryl; wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl may be substituted or unsubstituted; 
 each R 1  and R 2  is independently H or C 1-10  substituted or unsubstituted alkyl; 
 m is independently an integer from 0 to 10; 
 n is independently an integer from 0 to 10; and 
 each p is independently an integer from 0 to 5; or 
 a pharmaceutically acceptable salt form thereof. 
 
     
     
         35 . The composition of  claim 34 , wherein the carrier, excipient, or diluent is a physiologically acceptable saline solution. 
     
     
         36 . The composition of  claim 34 , wherein the composition further comprises a pain relief agent, an antinausea agent, or an additional anticancer agent.